Clarus Corp.

Philip A. Baratelli, 41, has served as our Chief Financial Officer, Secretary and Treasurer since February 2007. Since February 2007, Mr. Baratelli has also served as Chief Financial Officer for Kanders & Company, Inc., a private investment firm principally owned and controlled by Mr. Warren B. Kanders that makes investments in and provides consulting services to public and private entities. Since April 2007, Mr. Baratelli has served as the Chief Financial Officer for Highlands Acquisition Corp., a publicly-held blank check company formed with a focus on acquiring a business in the healthcare industry. From June 2001 to February 2007, Mr. Baratelli was the Corporate Controller and Treasurer of Armor Holdings, Inc., a manufacturer and supplier of military vehicles, armored vehicles and safety and survivability products and systems serving aerospace & defense, public safety, homeland security and commercial markets. From February 1998 to February 2001, Mr. Baratelli was employed by PricewaterhouseCoopers LLP in various positions ranging from Associate to Senior Associate. From 1991 to 1997, Mr. Baratelli worked for Barnett Banks, Inc. in various finance and credit analysis positions. Mr. Baratelli received a Bachelor of Science in finance from Florida State University in 1989 and a Bachelor of Business Administration in accounting from the University of North Florida in 1995. Mr. Baratelli is a Certified Public Accountant.

Linda started with CLARUS Corporation in 1993 as an interviewer and moved into the Director's position in 1997. Linda has experience in all phases of interviewing from personal and telephone interviews with community members to business interviews with busy corporate executives and doctors.

Burtt R. Ehrlich , 69, has served as one of our directors since June 2002. Prior to the completion of the acquisition of Armor Holdings, Inc., by BAE Systems plc on July 31, 2007, Mr. Ehrlich served as a director of Armor Holdings, Inc. since January 1996. Mr. Ehrlich has also served as a member of the Board of Directors of Langer, Inc. since February 2001. Mr. Ehrlich is also a member of the Board of Trustees of The Arbitrage Fund, a registered investment company. Mr. Ehrlich served as Chairman and Chief Operating Officer of Ehrlich Bober Financial Corp. (the predecessor of Benson Eyecare Corporation) from December 1986 until October 1992, and as a director of Benson Eyecare Corporation from October 1992 until November 1995.

Dr. Cunningham joined Clarus Ventures with more than 20 years experience in the biomedical and biopharmaceutical sectors. Prior to Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc, where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 200 publications. He is an Adjunct Clinical Professor of Ophthalmology at Stanford University, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University, a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute, and completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF. Dr. Cunningham is a member of the Board of Directors for SARcode Inc., a member of the Scientific Advisory Boards of ESBAtech AG and Comentis Inc., and a Board observer for Ferrokin Biosciences, Pearl Therapeutics Inc., Taligen Therapeutics Inc., and Zogenix, Inc.

Linda Johns founded Clarus Consulting Group in 1999 (formerly known as GIT, Inc.). As a management consultant, she advises commercial and government clients as they establish and reengineer their management and business processes. Linda leads Clarus' engagements using her engineering training and experience in project management, business process reengineering, and change management. Her project experience ranges from highly sophisticated and technical applications to complex, multi-organizational programs. Her expertise in change management ensures that the new management and business processes are implemented throughout the entire organization.

Lorie O'Neill brings more than 14 years of high tech sales and marketing experience to Critial3 Marketing all centered on strategies and execution to drive revenue. Her leadership experience includes developing and executing company messaging and sales positioning, and building product marketing, industry marketing and lead generation organizations from the ground up at high tech companies such as Clarus and Radiant Systems. Lorie has also directed strategies for vertical industry programs, interactive marketing, product sales and channel marketing. Lorie leverages her experience in sales and marketing to prioritize and achieve the critical alignment necessary to drive effective marketing focused on real value and high impact results for sales. Lorie's successful sales and marketing career also includes technology leaders such as PeopleSoft, Hyperion Software and Dun & Bradstreet Software. Lorie is a CPA and graduated with a B.S. in Commerce from the University of Virginia.

Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired in 2005 by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company's intellectual property group. Prior to TransForm, Scott was an attorney specializing in mergers & acquisitions at the NYC-based law firm of Davis Polk & Wardwell where, among other things, he completed numerous public and private deals worth in excess of $1 billion, negotiated credit facilities of more than $10 billion and represented two companies during their initial public offerings. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a J.D. from University of Toronto and most recently an MBA from Harvard Business School, where he was a Baker Scholar.

Sarah assists the Project Manager in most phases of the project, including formatting and proofreading final reports, inputting data obtained for the evaluation of the College's market segments and obtaining and formatting occupational forecasts for Workforce Development Scans. She has experience in education as an instructor for Adult Basic Education.

Nicholas Sokolow , 59, has served as one of our directors since June 2002. Prior to the completion of the acquisition of Armor Holdings, Inc., by BAE Systems plc on July 31, 2007, Mr. Sokolow served as a member of the Board of Directors of Armor Holdings, Inc. since January 1996. Mr. Sokolow has also served as a member of the Board of Directors of Stamford Industrial Group, Inc., formerly known as Net Perceptions, Inc. ("SIG") since April 2004. Since 2007, Mr. Sokolow has been practicing at the law firm of Lebow & Sokolow LLP. From 1994 to 2007 Mr. Sokolow was a partner at the law firm of Sokolow, Carreras & Partners. From June 1973 until October 1994, Mr. Sokolow was an associate and partner at the law firm of Coudert Brothers. The affirmative vote of a plurality of the votes cast in person or by proxy at the Meeting is necessary for the election as directors of the four nominees named in this Proxy Statement (assuming a quorum of a majority of the outstanding shares of common stock is present).

Nicholas Sokolow , 59, has served as one of our directors since June 2002. Prior to the completion of the acquisition of Armor Holdings, Inc., by BAE Systems plc on July 31, 2007, Mr. Sokolow served as a member of the Board of Directors of Armor Holdings, Inc. since January 1996. Mr. Sokolow has also served as a member of the Board of Directors of Stamford Industrial Group, Inc., formerly known as Net Perceptions, Inc. ("SIG") since April 2004. Since 2007, Mr. Sokolow has been practicing at the law firm of Lebow & Sokolow LLP. From 1994 to 2007 Mr. Sokolow was a partner at the law firm of Sokolow, Carreras & Partners. From June 1973 until October 1994, Mr. Sokolow was an associate and partner at the law firm of Coudert Brothers. The affirmative vote of a plurality of the votes cast in person or by proxy at the Meeting is necessary for the election as directors of the four nominees named in this Proxy Statement (assuming a quorum of a majority of the outstanding shares of common stock is present).